Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly and Co's basal insulin peglispro shows novel mechanism of action


Saturday, 14 Jun 2014 01:00pm EDT 

Eli Lilly and Co:Announces new data regarding mechanism of action of basal insulin peglispro (BIL).When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the liver, BIL showed less activity in peripheral tissues, such as muscle and fat, than insulin glargine.1.In this study, researchers measured both glucose disposal rate (GDR) and endogenous glucose production (EGP) rate to characterize peripheral vs. hepatic insulin action.1.BIL, which was discovered and developed in Lilly Research Laboratories, is currently in Phase III clinical trials, and is among several diabetes molecules in Lilly's late-stage pipeline. 

Company Quote

59.074
1.282 +2.22%
19 Dec 2014